Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo

Journal of Controlled Release

Volumn 65, Issue 1-2, 2000, Pages 133-148

  Malik, N ^a   Wiwattanapatapee, R ^a   Klopsch, R ^a   Lorenz, K ^b   Frey, H ^b   Weener, J W ^c   Meijer, E W ^c   Paulus, W ^d   Duncan, R ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^d BASF SE   (Germany)

Author keywords

Biocompatibility; Dendrimers; Drug delivery; Gene delivery

Indexed keywords

BUTANE; DENDRIMER; DRUG CARRIER; ETHYLENEDIAMINE DERIVATIVE; IODINE 125; POLYAMIDOAMINE; POLYAMINE; POLYPROPYLENE; STARBURST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; GENE TARGETING; HUMAN; HUMAN CELL; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSCYTOSIS;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL SURVIVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEMOLYSIS; INDICATORS AND REAGENTS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICROSCOPY, ELECTRON, SCANNING; ORGANOSILICON COMPOUNDS; POLYAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SUCCINIMIDES; TISSUE DISTRIBUTION;

EID: 0034005436     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00246-1     Document Type: Article

References (42)

1. Nucci M.L., Shorr R., Abuchowski A. The therapeutic value of poly(ethylene glycol) modified proteins. Adv. Drug Deliv. Rev. 6:1991;133-151.
2. Maeda H., Konno T. Metamorphosis of neocarzinostatin to SMANCS: Chemistry, biology, pharmacology, and clinical effect of the first prototype anticancer polymer therapeutic. Maeda H., Endo K., Ishida N. Neocarzinostatin, The Past Present and Future of an Anticancer Drug. 1997;227-267 Springer-Verlag, Tokyo.
3. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs. 3:1992;175-210.
4. Duncan R., Dimitrijevic S., Evagororou E.G. The role of polymer conjugates in the diagnosis and treatment of cancer. Stp Pharma Sci. 6:1996;237-263.
5. S. Brocchini, R.Duncan, Polymer drug conjugates: Drug release from pendent linkers, in: E. Mathiowitz (Ed.), Encyclopedia of Controlled Drug Delivery, Wiley, New York, 1999, in press.
6. Vasey P., Twelves C., Kaye S.B., Wilson P., Morrison R., Duncan R., Thomson A., Hilditch T., Murray T., Burtles S., Cassidy J. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin): First member of a new class of chemotherapeutic agents: drug-polymer conjugates. Clin. Cancer Res. 5:1999;83-94.
7. Tomalia D.A., Naylor A.M., Goddard III W.A. Starburst dendrimers: molecular level control of size, shapes, surface chemistry, topology and flexibility from atoms to macroscopic matter. Angew. Chem., Int. Ed. 29:1990;138-175.
8. Newkome G.R., Zao Z.-Q., Baker G.R., Gupta V.K. Micelles. 1. Cascade molecules. A new approach to micelles. J. Org. Chem. 50:1985;2003-2004.
9. Buhleier E., Wehner W., Vogtle F. "Cascade" and "nonskid-chain-like" synthesis of molecular cavity topologies. Synthesis. 55:1978;155-158.
10. Hawker C.J., Frechet J.M.J. Preparation of polymers with controlled molecular architecture - A new approach to dendritic macromolecules. J. Am. Chem. Soc. 112:(21):1990;7638-7647.
11. Newkome G.R., Moorefield C.N., Vögtle F. Dendritic Molecules. 1996;1-261 VCH, New York.
12. Duncan R., Malik N. Dendrimers: Biocombatibility and potential for delivery of anticancer agents. Proc. Int. Symp. Control. Release Bioact. Mater. 23:1996;105-106.
13. N. Malik, E.G. Evagorou, R. Duncan, Dendrimer-platinate as a novel approach to cancer chemotherapy. Anti-Cancer Drugs (1999) to be submitted.
14. Haensler J., Szoka F.C. Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconj. Chem. 4:1993;372-379.
15. Tang M.X., Redemann C.T., Szoka F.C. Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconj. Chem. 7:1996;703-714.
16. Bielinska A., Kukowska-Latallo J.F., Johnson J., Tomalia D.A., Baker J. Jr. Regulation of in vitro gene expression using antisense oligonucleotide or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24:1996;2176-2182.
17. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R., Tomalia D.A., Baker J. Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. USA. 93:1996;4897-4902.
18. Raduchel B., Schmitt Willich H., Ebert J., Frezel T., Misselwitz B., Weinmann H.J. Synthesis and characterisation of novel dendrimer-based gadolinium complexes as MRI contrast agents for the vascular system. Abstr. Am. Chem. Soc. 216:1998;278.
19. Roy R. Recent deveopments in the rational design of multivalent glycoconjugates. Top. Curr. Chem. 187:1997;241-274.
20. Ashton P.R., Boyd S.E., Bown C.L., Jayaraman N., Nepogodiev S.A., Stoddart J.F. A convergent synthesis of carbohydrate-containing dendrimers. Chem. Eur. J. 2:1996;1115-1128.
21. Tam J.P. Synthetic peptide vaccine design, synthesis and properties of a high density multiple antigenic peptide system. Proc Natl. Acad. Sci. USA. 85:1988;5409-5413.
22. Jansen J.F.G.A., de Brabander-van den Berg E.M.M., Meijer E.W. Encapsulation of guest molecules into a dendritic box. Science. 266:1994;1226-1229.
23. Barth R.F., Adams D.M., Soloway A.H., Alam F., Darby M.V. Boronated starburst-monoclonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron capture therapy. Bioconj. Chem. 5:1994;58-66.
24. Yang W.L., Barth R.F., Adams D.M., Solway A.H. Intratumoural delivery of boronated epidermal growth factor for neutron capture therapy for brain tumours. Cancer Res. 57:1997;4333-4339.
25. Malik N., Wiwattanapatapee R., Duncan R. Dendritic polymers: Relationship of structure with biological properties. Proc. Int. Symp. Control. Release Bioact. Mater. 24:1997;527-528.
26. Wiwattanapatapee R., Carreno-Gomez B., Malik N., Duncan R. PAMAM dendrimers as a potential oral drug delivery system: uptake by everted rat intestinal sacs in vitro. J. Pharm. Pharmacol. 50:1998;99.
27. Tomalia D.A., Baker H., Dewald J., Hall M., Kallos G., Martin S., Roeck J., Smith P. A new class of polymers: Starburst-dendritic macromolecules. Polymer J. 17:1985;117-132.
28. de Brabander-van den Berg E.M.M., Meijer E.W. Poly(proyleneimine) dendrimers. Angew. Chem. Int. Ed. Engl. 32:1993;1308-1311.
29. Lorenz K., Mülhaupt R., Frey H., Rapp U., Mayer-Posner F.J. Carbosilane based dendritic polyols. Macromolecules. 28:1995;6657-6661.
30. Frey H., Lach C., Lorenz K. Heteroatom-based dendrimers. Adv. Mater. 10:1998;279.
31. R. Klopsch, S. Koch, A.-D. Schlueter, R. Duncan, Biocompatibility testing and convergent synthesis of water-soluble dendritic structures. J. Bioact. Compat. Polymers (1999) to be submitted.
32. Duncan R., Bakoo M., Riley M.L. Soluble drug carriers:haemocompatibility. Gomez-Fernandez J.C., Chapman D., Packer L. Progress in Membrane Biotechnology. 1991;253-265 Birkhauser Verlag, Basel, Switzerland.
33. Sgouras D., Duncan R. Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use: 1. Use of the tetrazolium-based colorimetric assay (MTT) as a preliminary screen for the evaluation of in vitro cytotoxicity. J. Mater. Sci. Med. 1:1990;67-78.
34. Plummer D.T. Introduction To Practical Biochemistry. 1978;136-144 McGraw Hill, London.
35. Carreno-Gomez B., Duncan R. Evaluation of the biological properties of soluble chitosan and chitosan microspheres. Int. J. Pharm. 148:(2):1997;231-240.
36. Roberts J.C., Bhalgat M.K., Zera R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst™ dendrimers. J. Biomed. Mater. Res. 30:1996;53-65.
37. Richardson S., Ferruti P., Duncan R. Poly(amidoamine)s as potential endoosmolytic polymers: Evaluation in vitro and body distribution in normal and tumour-bearing animals. J. Drug Targeting. 6:1999;391-404.
38. Wilbur D.S., Pathare P.P., Hamlin D.K., Buhler K.R., Vessella R.L. Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination and evaluation of biotinylated starburst dendrimers. Bioconj. Chem. 9:1998;813-825.
39. Margerum L.D., Campion B.K., Koo M., Shargill N., Lai J.J., Marumoto A., Sontum P.C. Gadolinium (III) DO3A macrocycles and polyethylene glycol coupled to dendrimers - Effect of molecular weight on physical and biological properties of macromolecular resonance imaging contrast agents. J. Alloys Compounds. 249:1997;185-190.
40. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 6:1986;6387-6392.
41. Yang W.L., Barth R.F., Adams D.M., Soloway A.H. Intratumoural delivery of boronated epidermal growth factor for neutron capture therapy of brain tumours. Cancer Res. 57:1997;4333-4339.
42. Plank C., Mechtler K., Szoka F.C., Wagner E. Activation of the complement system by synthetic DNA complexes: A potential barrier to intravenous gene delivery. Hum Gene Ther. 7:(12):1996;1437-1446.